P10636 |
TAU_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10636 |
TAU_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P10636 |
TAU_HUMAN |
Mild neurocognitive disorder [ICD-11: 6D71] |
P10636 |
TAU_HUMAN |
Choreiform disorder [ICD-11: 8A01] |
P10636 |
TAU_HUMAN |
Parkinsonism [ICD-11: 8A00] |
P10636 |
TAU_HUMAN |
Central nervous system disease [ICD-11: 8A04-8D87] |
P10636 |
TAU_HUMAN |
Neurodegenerative disorder [ICD-11: 8A20-8A23] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
O75874 |
IDHC_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
O75874 |
IDHC_HUMAN |
Liver cancer [ICD-11: 2C12] |
O75874 |
IDHC_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
O75874 |
IDHC_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
O75874 |
IDHC_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
O75874 |
IDHC_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
O94782 |
UBP1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q13148 |
TADBP_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q13148 |
TADBP_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P28223 |
5HT2A_HUMAN |
Acute diabete complication [ICD-11: 5A2Y] |
P28223 |
5HT2A_HUMAN |
Anxiety disorder [ICD-11: 6B00-6B0Z] |
P28223 |
5HT2A_HUMAN |
Cerebral ischaemia [ICD-11: 8B1Z] |
P28223 |
5HT2A_HUMAN |
Mood disorder [ICD-11: 6A60-6E23] |
P28223 |
5HT2A_HUMAN |
Parkinsonism [ICD-11: 8A00] |
P28223 |
5HT2A_HUMAN |
Pituitary gland disorder [ICD-11: 5A60-5A61] |
P28223 |
5HT2A_HUMAN |
Schizophrenia [ICD-11: 6A20] |
P28223 |
5HT2A_HUMAN |
Sexual dysfunction [ICD-11: HA00-HA01] |
P28223 |
5HT2A_HUMAN |
Chronic insomnia [ICD-11: 7A00] |
P28223 |
5HT2A_HUMAN |
Chronic pain [ICD-11: MG30] |
P28223 |
5HT2A_HUMAN |
Depression [ICD-11: 6A70-6A7Z] |
P28223 |
5HT2A_HUMAN |
Insomnia [ICD-11: 7A00-7A0Z] |
P28223 |
5HT2A_HUMAN |
Post-traumatic stress disorder [ICD-11: 6B40] |
P28223 |
5HT2A_HUMAN |
Sleep-wake disorder [ICD-11: 7A00-7B2Z] |
P28223 |
5HT2A_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P28223 |
5HT2A_HUMAN |
Attention deficit hyperactivity disorder [ICD-11: 6A05] |
P28223 |
5HT2A_HUMAN |
Bipolar disorder [ICD-11: 6A60] |
P28223 |
5HT2A_HUMAN |
Chronic kidney disease [ICD-11: GB61] |
P28223 |
5HT2A_HUMAN |
Dementia [ICD-11: 6D80-6D8Z] |
P28223 |
5HT2A_HUMAN |
Glaucoma [ICD-11: 9C61] |
P28223 |
5HT2A_HUMAN |
Idiopathic interstitial pneumonitis [ICD-11: CB03] |
P28223 |
5HT2A_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P28223 |
5HT2A_HUMAN |
Schizoaffective disorder [ICD-11: 6A21] |
P28223 |
5HT2A_HUMAN |
Social anxiety disorder [ICD-11: 6B04] |
P28223 |
5HT2A_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P28223 |
5HT2A_HUMAN |
Cardiovascular disease [ICD-11: BA00-BE2Z] |
P28223 |
5HT2A_HUMAN |
Psychotic disorder [ICD-11: 6A20-6A25] |
P28223 |
5HT2A_HUMAN |
Prostate hyperplasia [ICD-11: GA90] |
P28223 |
5HT2A_HUMAN |
Addictive disorder [ICD-11: 6C50-6C5Z] |
P28223 |
5HT2A_HUMAN |
Haemorrhoids [ICD-11: DB60] |
P28223 |
5HT2A_HUMAN |
Hypertension [ICD-11: BA00-BA04] |
P28223 |
5HT2A_HUMAN |
Migraine [ICD-11: 8A80] |
P28223 |
5HT2A_HUMAN |
Pancreatitis [ICD-11: DC31-DC34] |
P28223 |
5HT2A_HUMAN |
Substance abuse [ICD-11: 6C40] |
P28223 |
5HT2A_HUMAN |
Central nervous system disease [ICD-11: 8A04-8D87] |
P28223 |
5HT2A_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
P28335 |
5HT2C_HUMAN |
Depression [ICD-11: 6A70-6A7Z] |
P28335 |
5HT2C_HUMAN |
Migraine [ICD-11: 8A80] |
P28335 |
5HT2C_HUMAN |
Obesity [ICD-11: 5B80-5B81] |
P28335 |
5HT2C_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P28335 |
5HT2C_HUMAN |
Pituitary gland disorder [ICD-11: 5A60-5A61] |
P28335 |
5HT2C_HUMAN |
Psychoactive substances use disorder [ICD-11: 6C4G] |
P28335 |
5HT2C_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P28335 |
5HT2C_HUMAN |
Attention deficit hyperactivity disorder [ICD-11: 6A05] |
P28335 |
5HT2C_HUMAN |
Chronic insomnia [ICD-11: 7A00] |
P28335 |
5HT2C_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P28335 |
5HT2C_HUMAN |
Parkinsonism [ICD-11: 8A00] |
P28335 |
5HT2C_HUMAN |
Schizophrenia [ICD-11: 6A20] |
P28335 |
5HT2C_HUMAN |
Sleep-wake disorder [ICD-11: 7A00-7B2Z] |
P28335 |
5HT2C_HUMAN |
Tonus and reflex abnormality [ICD-11: MB47] |
P28335 |
5HT2C_HUMAN |
Acute diabete complication [ICD-11: 5A2Y] |
P28335 |
5HT2C_HUMAN |
Psychotic disorder [ICD-11: 6A20-6A25] |
P28335 |
5HT2C_HUMAN |
Substance abuse [ICD-11: 6C40] |
P28335 |
5HT2C_HUMAN |
Anxiety disorder [ICD-11: 6B00-6B0Z] |
P28335 |
5HT2C_HUMAN |
Mood disorder [ICD-11: 6A60-6E23] |
P28335 |
5HT2C_HUMAN |
Dissociative neurological symptom disorder [ICD-11: 6B60] |
P28482 |
MK01_HUMAN |
Melanoma [ICD-11: 2C30] |
P28482 |
MK01_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P28482 |
MK01_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P28482 |
MK01_HUMAN |
Arteries/arterioles disorder [ICD-11: BD52] |
P28482 |
MK01_HUMAN |
Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] |
P28482 |
MK01_HUMAN |
Transplant rejection [ICD-11: NE84] |
P28482 |
MK01_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
P28482 |
MK01_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P41595 |
5HT2B_HUMAN |
Depression [ICD-11: 6A70-6A7Z] |
P41595 |
5HT2B_HUMAN |
Pituitary gland disorder [ICD-11: 5A60-5A61] |
P41595 |
5HT2B_HUMAN |
Psychotic disorder [ICD-11: 6A20-6A25] |
P41595 |
5HT2B_HUMAN |
Attention deficit hyperactivity disorder [ICD-11: 6A05] |
P41595 |
5HT2B_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
P41595 |
5HT2B_HUMAN |
Coronary atherosclerosis [ICD-11: BA80] |
P41595 |
5HT2B_HUMAN |
Anxiety disorder [ICD-11: 6B00-6B0Z] |
P41595 |
5HT2B_HUMAN |
Migraine [ICD-11: 8A80] |
P41595 |
5HT2B_HUMAN |
Irritable bowel syndrome [ICD-11: DD91] |
Q96KQ7 |
EHMT2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q96KQ7 |
EHMT2_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
Q96KQ7 |
EHMT2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08185 |
CBG_HUMAN |
Asthma [ICD-11: CA23] |
P08185 |
CBG_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P08185 |
CBG_HUMAN |
Respiratory system disease [ICD-11: CB40-CB7Z] |
P08185 |
CBG_HUMAN |
Retinopathy [ICD-11: 9B71] |